Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Champions Oncology (CSBR) announced advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and ...

Each year, over 1.2 million Americans receive a cancer diagnosis, a journey that can be both overwhelming and daunting.